Review|Articles in Press, 103681

The role of plasmapheresis in the pulmonary-renal syndrome

Published:February 24, 2023DOI:
      A pulmonary renal syndrome is diagnosed when the combination of a rapid progressive glomerulonephritis (RPGN) and diffuse pulmonary hemorrhage (DAH) are present. Both are severe disease manifestations that are associated with a considerable morbidity and mortality. Most frequently, the underlying cause is a small vessel vasculitis due to anti-neutrophil cytoplasmatic antibody (ANCA) associated vasculitis (AAV) or anti-glomerular basement membrane disease. Other vasculitis’s and connective tissue diseases such as Systemic Lupus Erythematosus and Rheumatoid Arthritis present the more rare causes of this syndrome.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jenette J.C.
        • Wilkman A.S.
        • Falk R.J.
        Anti-Neutrophil cytoplasmatic autoantibody-associated glomerulonephritis and vasculitis.
        Am J Pathol. 1989; 135: 921-930
        • Pedchenko V.
        • Bondar O.
        • Fogo A.B.
        • Vanacore R.
        • Voziyan P.
        • Kitching A.R.
        • et al.
        Molecular architecture of the Goodpasture autoantigen in Anti-GBM Nephritis.
        N Engl J Med. 2010; 363: 4343-4354
        • Walsh M.
        • Collister D.
        • Zeng L.
        • Merkel P.A.
        • Pusey C.D.
        • Guyatt G.
        • et al.
        The effects of plasma exchange in patients with ANCA-associated vasculitis; an updated systematic review and meta-analysis.
        BMJ. 2022; 376e064604
        • Walsh M.
        • Casian A.
        • Flossmann O.
        • Westman K.
        • Höglund P.
        • Pusey C.
        • et al.
        EUVAS). Long-term follow-up of patients with severe ANCAassociated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear.
        Kidney Int. 2013; 84 (European Vasculitis Study Group): 397-402
        • Walsh M.
        • Merkel P.A.
        • Peh C.-A.
        • Szpirt W.M.
        • Puéchal X.
        • Fujimoto S.
        • et al.
        PEXIVAS Investigators. Plasmaexchange and glucocorticosteroids in severe ANCA-associated vasculitis.
        N Engl J Med. 2020; 382: 622-631
        • Lockwood C.M.
        • Boulton-Jones J.M.
        • Lowenthal R.M.
        • Simpson I.J.
        • Peters D.K.
        Recovery from Goodpasture’s syndrome after immunosuppressive treatment and plasmapheresis.
        Br Med J. 1975; 2: 252-254
        • Johnson J.P.
        • Moore Jr J.
        • Austin 3rd H.A.
        • Balow J.E.
        • Antonovych T.T.
        • Wilson C.B.
        Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors.
        Medicine. 1985; 64: 219-227
        • Moussi-Frances J.
        • Sallée M.
        • Jourde-Chiche N.
        Apheresis to treat systemic vasculitis.
        Jt Bone Spine. 2018; 85: 177-183
        • Tesar V.
        • Hruskova Z.
        Complement inhibition in ANCA-associated vasculitis.
        Front Immunol. 2022; 13888816
        • Nithagon P.
        • Cortazar F.
        • Shah S.I.
        • Weins A.
        • Laliberte K.
        • Jeyabalan A.
        • et al.
        Eculizumab and complement activation in anti-glomerular basement membrane disease.
        Kidney Int Rep. 2021; 6: 2713-2717